Adenovirus-mediated gene therapy of liver diseases

Seminars in Liver Disease

Volumn 19, Issue 1, 1999, Pages 49-59

  Ilan, Yaron ^a   Saito, Hidetsugu ^b   Thummala, Narsing R ^c   Roy Chowdhury, Namita ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adenoviral vectors; Gene therapy; Hepatic malignancies; Hereditary diseases; Infectious diseases

Indexed keywords

BETA GALACTOSIDASE; BILIRUBIN; FUMARYLACETOACETASE; GLUCURONOSYLTRANSFERASE; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUTRALIZING ANTIBODY; ORNITHINE CARBAMOYLTRANSFERASE; PROTEIN P53; VIRUS DNA;

ADENOVIRUS; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; CANCER IMMUNOTHERAPY; CRIGLER NAJJAR SYNDROME; CYTOTOXIC T LYMPHOCYTE; EPISOME; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HEPATITIS; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LIVER TUMOR; MUCOPOLYSACCHARIDOSIS TYPE 7; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSGENE; TYROSINEMIA; VIRUS RECOMBINANT;

EID: 0032948552     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007097     Document Type: Review

References (86)

1. Shenk T. Adenoviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996, pp 2111-2148
2. Bergelson JM, Krithivas A, Cell L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998;72:415-419
3. Chiocca S, Cotton M. In: Chiocca EA, Breakfield XO (eds). Characteristics of Adenovirus Vectors in Gene Therapy for Neurological Disorders and Brain Tumors, 1st ed. Totowa, NJ: Humana Press, 1998, pp 39-52
4. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7:215-222
5. liot M, Adam M, Gallais I, et al. High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes. J Virol 1997;71: 5375-5381
6. Guo ZS, Wang LH, Eisensmith RC, et al. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996;9:802-810
7. Loser P, Sandig V, Kirillova I, et al. Evaluation of HBV promoter for use in hepatic gene therapy. Biol Chem Hoppe Seyler 1996;377:187-193
8. Lieber A, He CY, Kirillova I, et al. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996;70:8944-8960
9. kuyama T, Fujino M, Li X-K, et al. Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther 1998;5:1047-1053
10. Sato Y, Tanaka K, Lee G, et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun 1998;244:455-462
11. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in P53 deficient human tumor cells Science 1996;274:373-376
12. Heise C, Sampson-Johannes A, Williams A. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-645
13. Hall AR, Dix BR, O'Carroll SJ, et al. P53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998;4:1068-1072
14. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigen create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;67:2004-2015
15. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996, pp 2149-2171
16. Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long term expression. Proc Natl Acad Sci U S A 1995;92:1401-1405
17. Yang Y, Greenough K, Wilson JM. Transient immuneblockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther 1996;3:412-420
18. Ilan Y, Jona VK, Sengupta K, et al. Transient immunosuppression with FK506 permits long term expression of therapeutic genes introduced into the liver using recombinant adenoviruses. Hepatology 1997;26:949-956
19. Ilan Y, Jona VK, Prakash R, et al. Long term adenovirus directed gene therapy in rats and rabbits using transient FK-506 treatment. Hepatology 1996;24:48A
20. Bluestone JA. New prospectives of CD28-B7 mediated T cell costimulation. Immunity 1995;2:555-559
21. Hathcock KS, Laszlo G, Dickler HB, et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function. Science 1993;262:905-909
22. Kearne ER, Walunas TL, Karr RW. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4 T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA4. J Immunol 1995;155:1032-1036
23. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 1995;270:985-988
24. Wallace PM, Rodgers JN, Leytze GM, et al. Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treament. J Immunol 1995;154: 5885-5895
25. Kay MA, Meuse L, Gown AM, et al. Transient immunomoclulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 1997;94:4686-4691
26. Takahashi M, Ilan Y, Sengupta K, et al. Induction of tolerance to recombinant adenoviruses by injection into newborn rats: Long term amelioration of hyperbilirubinemia in Gunn rats. J Biol Chem 1996;271:26536-26542
27. Ilan Y, Sauter B, Roy Chowdhury N, et al. Prenatal tolerization to recombinant adenovirus permits long term correction of bilirubin glucuronidation defect in Gunn rats by repeated adenovirus-mediated gene therapy. Gastroenterology 1998;114:261 A
28. Huang TJ, Roy Chowdhury J, Lahiri P, et al. Prenatal diagnosis of bilirubin UDP glucuronusyl transferase deficiency in rats by genomic DNA analysis. Hepatology 1992;16:756-762
29. Roy Chowdhury J, Wolkoff AW, Roy Chowdhury N, Arias IM. In: Scriver CR, Beandet AL, Sly WS, Valle D (eds). Hereditary Jaundice and Disorders of Bilirubin Metabolism. Vol. II. New York: McGraw-Hill, 1995, pp 2161-2208
30. Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long term gene therapy in Gunn rats. J Clin Invest 1996;98:2640-2647
31. Weiner H., Oral tolerance. Proc Natl Acad Sci U S A 1994; 91:10762-10765
32. Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343
33. Javed NH, Gienapp IE, Cox KL, et al. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 1995;155:1599-1605
34. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigen in multiple sclerosis. Science 1993;261:1321-1324
35. Chen YH, Weiner HL. Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Ann N Y Acad Sci 1996;778:111-121
36. Ian Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors. J Clin Invest 1997;99:1098-1106
37. Ilan Y, Roy Chowdhury N, Sauter B, et al. A critical role of the liver in inducing oral tolerance to adenoviral vectors for long term gene therapy. Gastroenterology 1998;114:260A
38. Ilan Y, Sauter B, Roy Chowdhury N, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with preexisting immunity to adenovirus. Hepatology 1998;27:1368-1376
39. Ilan Y, Prakash R, Jona VK, et al. Adoptive transfer of tolerance from rats tolerized to adenoviral antigens allows long term adenovirus-mediated gene therapy in Gunn rats. Hepatology 1996; 24:304
40. Yang Y, Nunes FA, Berencsi K, et al. Inactivation of E2a in recombinant adenoviruses limits cellular immunity and improves the prospect of gene therapy of cystic fibrosis. Proc Natl Acad Sci U S A 1994;7:362-369
41. Fisher KJ, Choi H, Burda J, et al. Recombinant adenovirus deleted of all viral genes for genes for gene therapy of cystic fibrosis. Virology 1996;217:11-22
42. Chirmule N, Hughes JV, Gao GP, et al. Role of E4 in eliciting CD4 T cell and B cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998;72: 6138-6145
43. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proc Natl Acad Sci U S A 1998;95:11377-11382
44. Horwitz MS, Tufariello J. Grunhaus A, et al. Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Curr Top Microbiol Immunol 1995;199:195-211
45. Lee MG, Abina MA, Haddada H, et al. The constitutive expression of the immunodulatory gp 19K protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995;2:256-262
46. Feuerbach D, Etteldorf S, Ebenau-Jehle C, et al. Identification of amino acids within the MHC molecule important for the interaction with the adenovirus protein E3/19K. J Immunol 1994;153: 1626-1636
47. Li Y, Kang J, Horwitz MS. Interaction of an adenovirus 14.7 kDa protein inhibitor of TNF acytolysis with a new member of the GT-Pase superfamily of signal transducers. J Virol 1996;56: 734-741
48. Turariello, JM, Sangho C, Horwitz M.S. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolis, increases the virulence of vcaccinia virus in severe combined immunodeficient mice. Proc Natl Acad Sci U S A 1994;91: 10987-10991
49. Efrat S, Fejer M, Brownlee G, et al. Prolonged survival of pancreatic islet allograft mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci U S A 1995;92:6947-6951
50. Polier W, Schneider-Rasp S, Liebert U, et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther 1996;63:521-530
51. Ilan Y, Droguett, G, Roy Chowdhury N, et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A 1997;94: 2587-2592
52. Ilan Y, Sauter B, Roy Chowdhury N, et al. Expression of adenoviral E3 gene production in normal rat hepatocytes prevents their rejection upon transplantation into allogeneic Gunn rats. Hepatology 1997;26:490A
53. Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994;269:17960-17964
54. Jansen PLM, Bosma PJ, Roy-Chowdhury J. Molecular biology of bilirubin metabolism. In: Boyer JL, Ockner RK (eds). Progress in Liver Diseases. Vol. XIII. Philadelphia: WB Saunders, 1995, pp 125-150
55. Ohashi T, Watabe K, Uehara K, et al. Adenovirus-mediated gene transfer and expression of human β-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VlI mice. Proc Natl Acad Sci U S A 1997;94: 1287-1292
56. Overturf K, al Dhalimy M, Ou CN, et al. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrostnemia type I. Hum Gene Ther 1997;8:513-521
57. Kiwaki K, Kanegae Y, Saito I, et al. Correction of ornithine transcarbamylase deficiency in adult spfash mice and OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum Gene Ther 1996;7:821-830
58. Excoffon KJ, Liu G, Miao L, et al. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arteriosclerosis Thromb Vasc Biol 1997;17: 2532-2539
59. Liu G, Excoffon KJ, Benoit P, et al. Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Hum Gene Ther 1997;8:205-214
60. Kozarsky KF, Joose K, Donahee M, et al. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996;13:54-62
61. Zsigmond E, Kobayashi K, Tzung KW, et al. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther 1997;8:1921-1933
62. Kozarsky K, Donahee MH, Rigotti A, et al. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997;387:414-417
63. Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996;271:6852-6860
64. Greeve J, Jona VK, Roy-Chowdhury N, et al. Hepatic gene transfer of the catalytic subunit of the apolypoprotein B mRNA editing enzyme, APOBEC-1, leads to reduction of LDL in normal and Watanabe heritable hyperlipidemic rabbits. J Lipid Res 1996;37:2001-2017
65. Scaglioni P, Melegari M, Takahashi M, et al. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996;24:1010-1017
66. He XS, Chen HS, Chu K, Rivkina M, Robinson WS. Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc Natl Acad Sci U S A 1996;93:7274-7278
67. Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996;70:8782-8791
68. Dachs GU, Dougherty GJ, Stafford IJ, et al. Targeting gene therapy to cancer: A review. Oncol Res 1997;9:313-325
69. Qian C, Idoate M, Bilbao R, et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther 1997;8:349-358
70. Block A, Chen SH, Kosai K, et al. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors. Pancreas 1997;15:25-34
71. Pederson LC, Buchsbaum DJ, Vickers SM, et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997;57:4325-4332
72. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55:581-589
73. Chen L, Yu LJ, Waxman DJ. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 1997;57:4830-4837
74. Mohr L, Shankara S, Roberts B, et al. Efficient tumor cell killing and pronounced bystander effect by adenovirus mediated transfer of the E. coli purine nucleoside phosphorylase gene to hepatocellular carcinoma cells. Hepatology 1998;28:504A
75. Huang H, Chen SH, Kosai K, Finegold MJ, Woo SL. Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther 1996;3:980-987
76. Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 1997;8:2173-2182
77. Bramson J, Hitt M, Gallichan WS, et al. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996;7:333-342
78. Bramson J, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996;7: 1995-2002
79. Chen L, Chen D, Block E, et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997; 159:351-359
80. Caruso M, Pham Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996;92:11302-11306
81. Siders WM, Wright PW, Hixon JA, et al. T cell and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J Immunol 1998;160:5465-5474
82. de Roos WK, Fallaux FJ, Marinelli AAWKS, et al. Isolated-organ perfusion for local gene delivery: Efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997;4:55-62
83. Olthoff KM, Judge TA, Gelman AE, et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: Survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat Med 1998;4:194-200
84. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996;70:7498-7509
85. Eiseler KA, Leinwand L, Gall J, et al. Circumventing the immune resposne to adenovirus-mediated gene therapy. Gene Ther 1996;3:154-162
86. Bilbao G, Feng M, Rancourt C, et al. Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997;11:624-634